title: How should we prescribe lapatinib to our patients: once daily or twice daily, and at what dose?
authors.forename: Mariangela
authors.initials: M
authors.lastname: Ciccarese
authors.forename: Vito
authors.initials: V
authors.lastname: Lorusso
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D000077341:Lapatinib; D011092:Polyethylene Glycols; D011799:Quinazolines / Q000008:administration & dosage* / Q000493:pharmacokinetics; D011994:Recombinant Proteins; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D011994:Recombinant Proteins; D043823:Taxoids; D000077341:Lapatinib; D016179:Granulocyte Colony-Stimulating Factor; D000077143:Docetaxel; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim